



— FACT BOOK —
Supplementary Materials
Financial Results <2Q FY2015>

Otsuka Holdings Co., Ltd.

Corporate Philosophy

Otsuka-people creating new products for better health worldwide

These words embody our commitment to:

- Creating our own unique and innovative products
- Improving human health and well-being
- Contributing to the lives of people worldwide

In keeping with this corporate philosophy and Otsuka's mottoes "*JISSHO*" (Proof through Execution) and "*SOZOSEI*" (Creativity), we strive to utilize our Group's unique assets and skills to develop differentiating scientific solutions which contribute to the lives of people worldwide in the form of innovative and creative products ranging from pharmaceuticals to consumer products.

Otsuka Group is striving to cultivate a culture and a dynamic corporate climate reflecting our vision as a health-care company. As such we are dedicated to achieving global sustainability, to our relationships with local communities and to the protection of the natural environment.


Corporate profile

Company name	Otsuka Holdings Co., Ltd.
Established	July 8, 2008
President and Representative Director, CEO	Tatsuo Higuchi
Capital	JPY 81,690 million
Registered address	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan
Tokyo headquarters	Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan
URL	http://www.otsuka.com/en/


			Page
I	Financial Highlights	• • • • • • • •	2
II	Consolidated Statements of Income	• • • • • • • •	4
	II-1 Sales of Major Products	• • • • • • • •	5
	II-2 Segment Information	• • • • • • • •	7
	II-3 Selling, General and Administrative Expenses	• • • • • • • •	8
III	Consolidated Balance Sheets	• • • • • • • •	9
IV	Consolidated Statements of Cash Flows	• • • • • • • •	11
V	Shareholders	• • • • • • • •	12
VI	Pipeline Information	• • • • • • • •	13

I. Financial Highlights


Net Sales (Billions of yen)




Operating Income (Billions of yen)



Ordinary Income (Billions of yen)



R&D expenses (Billions of yen)



Financial Highlights

		FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec)	FY2014 (Jan-Jun)	2Q FY2015	Estimate
						Standardizing the Company's business year	Standardizing the Company's business year <unaudited>	(Jan-Jun)	FY2015 (Jan-Dec)
									(Forecast as of Aug 2015)
Net sales	(Billions of yen)	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	733.9	745.8	1,380.0
	YoY	4.0%	2.4%	5.5%	19.3%	7.9%		1.6%	
Operating income	(Billions of yen)	126.3	148.7	169.7	198.7	196.5	82.9	103.2	120.0
	YoY	28.2%	17.7%	14.1%	17.1%	7.4%		24.5%	
Ordinary income	(Billions of yen)	128.4	152.1	184.5	215.2	217.2	88.0	109.4	125.0
	YoY	17.7%	18.5%	21.3%	16.7%	8.9%		24.4%	
Net income	(Billions of yen)	82.4	92.2	122.4	151.0	143.1	57.2	69.5	80.0
	YoY	22.1%	11.9%	32.8%	23.3%	2.7%		21.4%	
R&D expenses	(Billions of yen)	164.7	159.2	192.4	249.0	172.9	127.1	95.1	205.0
	YoY	8.4%	-3.3%	20.8%	29.4%	4.6%		-25.2%	
Overseas net sales	(Billions of yen)	552.5	579.7	622.7	824.4	757.0	445.1	444.4	741.0
	% of net sales	49.0%	50.2%	51.1%	56.8%	61.8%	60.6%	59.6%	

		FY2010	FY2011	FY2012	FY2013	FY2014	FY2014 (As of Jun 30)	2Q FY2015
							Standardizing the Company's business year <unaudited>	(As of Jun 30)
Total assets	(Billions of yen)	1,589.7	1,666.8	1,779.2	2,028.4	2,178.2	1,996.3	2,493.4
Net assets	(Billions of yen)	1,163.3	1,222.8	1,325.1	1,510.8	1,658.6	1,516.9	1,726.0
Shareholders' equity ratio	(%)	72.4	72.5	73.7	73.2	74.7	74.6	67.9

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

(Billions of yen)

Net sales by business segment	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year <unaudited>	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
Net sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	733.9	745.8	1.6%	1,380.0
Pharmaceutical business*	751.1	782.2	850.9	1035.1	883.5	533.7	520.9	-2.4%	903.0
Nutraceutical business*	258.7	254.8	251.8	287.1	238.2	134.1	154.4	15.1%	330.0
Consumer products business*	47.9	49.2	46.9	43.9	34.5	21.5	20.9	-2.8%	42.0
Other business*	106.9	108.6	111.7	130.3	102.2	66.4	71.8	8.3%	150.0
Eliminations/corporate	-37.0	-40.3	-43.1	-43.7	-34.2	-21.8	-22.2		-45.0

*Intersegment sales are included.

(Billions of yen)

Operating income by business segment	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year <unaudited>	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
Operating income	126.3	148.7	169.7	198.7	196.5	82.9	103.2	24.5%	120.0
Pharmaceutical business	142.8	168.5	187.9	212.8	204.8	95.3	108.5	13.9%	
Nutraceutical business	18.4	22.1	21.4	25.4	21.9	7.2	11.9	64.9%	
Consumer products business	-2.2	-2.3	-2.4	-2.2	-1.4	-0.3	-1.7		
Other business	4.4	1.9	3.9	7.2	5.5	3.2	3.6	11.4%	
Eliminations/corporate	-37.1	-41.6	-41.0	-44.5	-34.3	-22.6	-19.2		

(Reference) Exchange rates used to translate operating results of overseas subsidiaries

(yen)

Exchange rate (Yen)	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec)	FY2014 (Jan-Jun) Standardizing the Company's business year <unaudited>	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
US\$	87.79	79.79	79.80	97.72	106.72	102.45	120.30	17.9	120.00
Euro	116.27	111.12	102.55	129.77	140.20	140.42	134.10	-6.3	134.00

ROE / EPS / Dividend	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec)	FY2014 (Jan-Jun) Standardizing the Company's business year <unaudited>	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
ROE (Return on equity: %)	7.9	7.8	9.7	10.8	9.2	3.9	4.2	0.3	4.9
EPS (Earnings per share: yen)	164.5	165.2	221.9	278.1	264.2	105.6	128.2	22.6	147.7
Annual dividends per share (yen)	28.0	45.0	58.0	65.0	75.0	-	50.0	-	100.0
Payout ratio (%)	17.3%	27.2%	26.1%	23.4%	28.4%	-	39.0%	-	67.7%

* On June 30, 2009, a twenty-for-one stock split was executed by way of a free share distribution.

(Billions of yen)

Cash flow information	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec)	FY2014 (Jan-Jun) Standardizing the Company's business year <unaudited>	2Q FY2015 (Jan-Jun)	Change
Net cash provided by operating activities	87.7	147.6	119.3	226.4	88.5	80.2	227.5	147.3
Net cash used in investing activities	-131.5	-107.6	-91.2	-108.5	-28.7	2.1	-422.2	-424.4
Net cash provided (used in) by financing activities	113.6	-41.1	-71.9	-66.7	-36.0	-4.1	213.7	217.8
Cash and cash equivalents at end of period	387.3	384.2	347.6	417.5	456.5	501.7	463.5	-38.2

II. Consolidated Statements of Income

(Billions of yen)

	FY2010	%	FY2011	%	FY2012	%	FY2013	%	FY2014 (Apr-Dec) Consolidating the Company's business year	%	FY2014 (Jan-Jun) Consolidating the Company's business year	%	2Q FY2015 (Jan-Jun)	%	Change
Net sales	1,127.6	100.0%	1,154.6	100.0%	1,218.1	100.0%	1,452.8	100.0%	1,224.3	100.0%	733.9	100.0%	745.8	100.0%	1.6%
Cost of sales	379.0	33.6%	389.3	33.7%	393.8	32.3%	441.6	30.4%	346.3	28.3%	217.9	29.7%	215.1	28.8%	-1.3%
Gross profit	748.6	66.4%	765.3	66.3%	824.2	67.7%	1,011.1	69.6%	878.0	71.7%	516.0	70.3%	530.7	71.2%	2.8%
Selling, general and administrative expenses	622.3	55.2%	616.6	53.4%	654.6	53.7%	812.4	55.9%	681.5	55.7%	433.2	59.0%	427.5	57.3%	-1.3%
Promotion expenses	179.6		174.4		156.2		192.0		188.0		106.9		115.4		
Salaries and bonuses	80.3		81.3		85.4		107.1		89.9		48.5		66.4		
Reserve for bonuses	9.6		9.8		9.5		11.2		5.3		15.3		6.5		
Retirement benefit expenses	7.1		7.7		7.8		4.6		1.7		2.2		1.6		
Provision for directors' and audit & supervisory board members' retirement benefits	0.6		0.7		0.6		0.5		0.3		0.2		-		
Provision for directors' bonuses	0.3		0.4		0.3		0.6		0.6		1.0		-		
Depreciation	14.1		14.7		14.5		16.9		22.9		12.4		-		
Amortization of goodwill	4.6		4.7		4.8		3.7		3.8		2.2		12.8		
Research and development expenses	164.7	14.6%	159.2	13.8%	192.4	15.8%	249.0	17.1%	172.9	14.1%	127.1	17.3%	95.1	12.7%	-25.2%
Other	161.5		163.8		183.0		226.7		196.0		117.3		129.7		
Operating income	126.3	11.2%	148.7	12.9%	169.7	13.9%	198.7	13.7%	196.5	16.1%	82.9	11.3%	103.2	13.8%	24.5%
Non-operating income	10.8		8.6		16.6		18.8		23.1		9.7		9.7		
Interest income	1.3		1.6		1.4		1.3		1.3		0.6		0.8		
Dividend income	1.2		1.3		1.5		1.3		1.0		0.9		1.0		
Amortization of negative goodwill	2.5		2.5		2.5		2.6		1.8		1.2		1.5		
Equity in earnings of unconsolidated subsidiaries and affiliates	3.7		1.2		3.1		3.2		3.9		5.7		5.1		
Foreign exchange gain, net	-		-		6.2		7.9		12.9		-		-		
Other	2.0		2.1		2.0		2.5		2.3		1.3		1.3		
Non-operating expenses	8.6		5.2		1.8		2.3		2.4		4.6		3.5		
Interest expenses	1.5		1.7		1.2		1.2		1.7		0.8		2.0		
Foreign exchange loss, net	5.7		2.7		-		-		-		3.4		0.8		
Other	1.4		0.7		0.6		1.1		0.8		0.5		0.7		
Ordinary income	128.4	11.4%	152.1	13.2%	184.5	15.1%	215.2	14.8%	217.2	17.7%	88.0	12.0%	109.4	14.7%	24.4%
Extraordinary income	5.9		1.2		0.3		2.0		1.4		0.7		1.2		
Gain on sales of fixed assets	0.2		0.2		0.1		0.5		0.1		0.0		0.6		
Gain on change in equity	5.6		0.3		-		-		-		0.1		-		
Gain on sales of investment securities	-		-		-		0.3		0.0		0.3		-		
Gain on sales of shares of subsidiaries	-		-		-		0.3		-		-		-		
Subsidy income	-		-		-		0.9		0.9		-		0.3		
Gain on insurance adjustment	-		-		-		-		-		-		0.3		
Other	0.1		0.6		0.1		0.0		0.4		0.2		0.0		
Extraordinary loss	11.3		10.9		7.8		7.0		8.4		5.1		1.1		
Loss on retirement of fixed assets	0.9		0.6		0.7		0.9		0.6		0.5		0.2		
Impairment loss	2.8		2.7		2.6		3.4		5.4		2.0		0.1		
Loss on valuation of investment securities	1.9		3.7		4.4		0.2		1.5		0.2		-		
Extra retirement payments	-		-		-		1.9		0.6		1.9		-		
Provision of allowance for investment loss	0.6		-		-		-		-		-		-		
Loss on transfer of business	1.9		0.7		-		-		-		-		-		
Provision for loss on business liquidation	-		2.2		-		-		-		-		-		
Disaster related loss	1.8		0.3		-		-		-		-		-		
Loss on sales of subsidiaries' stocks	-		-		-		-		-		-		0.6		
Other	1.4		0.8		0.1		0.6		0.4		0.5		0.3		
Income before income taxes and minority interests	123.0		142.4		176.9		210.2		210.3		83.5		109.5		
Income taxes-current	33.6		55.0		62.0		81.3		46.2		37.1		13.6		
Income taxes-deferred	5.4		-5.4		-8.2		-23.6		19.8		-11.3		26.0		
Total income taxes	39.0		49.6		53.8		57.7		66.1		25.8		39.7		54.0%
Minority interests in net income	1.6		0.6		0.7		1.6		1.1		0.5		0.3		
Net income	82.4	7.3%	92.2	8.0%	122.4	10.1%	151.0	10.4%	143.1	11.7%	57.2	7.8%	69.5	9.3%	21.4%

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate.
The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

II-2. Sales of Major Products

【Pharmaceutical business】

(Billions of yen)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year <unaudited>	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
Antipsychotic agent ABILIFY	Otsuka Pharmaceutical	392.6	411.6	438.5	575.7	507.4	307.5	231.0	-24.9%	294.0
North America		308.3	316.1	336.1	455.5	416.5	239.1	175.6	-26.6%	196.0
<US\$ million>		<3,512>	<3,960>	<4,208>	<4,659>	<3,900>	<2,333>	<1,460>	-37.4%	<1,630>
Japan		23.0	24.8	28.6	34.4	23.7	15.5	16.9	8.9%	38.0
Others		61.2	70.7	73.9	85.8	67.2	52.8	38.4	-27.2%	60.0
Antipsychotic agent/ Depot injection Abilify Maintena	Otsuka Pharmaceutical				4.3	14.4	6.1	17.2	182.3%	41.0
Anti-platelet agent Pletal/Pletal	Otsuka Pharmaceutical	53.2	50.3	45.8	44.2	26.2	18.2	15.7	-13.5%	32.0
Japan		46.5	44.1	40.1	36.8	20.7	14.5	11.7	-19.1%	23.5
Others		6.7	6.2	5.7	7.4	5.5	3.7	4.0	8.6%	8.5
Anti-gastritis and anti-gastric ulcer agent Mucosta	Otsuka Pharmaceutical	30.7	28.7	23.0	22.0	12.9	9.2	8.1	-12.2%	16.0
Japan		27.8	26.0	20.5	18.8	10.1	7.4	5.8	-22.6%	11.5
Others		2.9	2.7	2.5	3.1	2.7	1.7	2.3	32.6%	4.5
Anti-metabolite TS-1	Taiho Pharmaceutical	37.1	36.5	37.0	37.4	24.0	15.0	14.9	-0.5%	30.0
Anti-metabolite UFT	Taiho Pharmaceutical	15.7	12.9	11.2	9.5	6.3	4.1	3.7	-9.8%	7.0
Reduced folic acid formulation Uzel	Taiho Pharmaceutical	14.1	12.7	13.2	11.9	7.9	5.1	5.1	1.1%	10.0
Antineoplastic Lonsurf	Taiho Pharmaceutical					2.3	0.6	1.5	140.5%	3.5
Urinary incontinence /frequency treatment BUP-4	Taiho Pharmaceutical	7.0	6.3	5.6	4.7	2.8	2.0	1.6	-17.6%	3.5
5-HT ₃ receptor antagonist Aloxi	Taiho Pharmaceutical	4.3	7.9	10.0	11.0	8.8	5.2	6.0	15.4%	12.5
Antineoplastic Abraxane	Taiho Pharmaceutical	1.1	3.2	3.7	8.8	8.2	4.7	9.0	91.6%	18.5
Antiepileptic E Keppra	Otsuka Pharmaceutical	0.8	4.8	10.5	15.8	13.2	7.9	10.1	27.3%	24.5
V ₂ -vasopressin receptor antagonist Samsca	Otsuka Pharmaceutical	3.2	6.7	12.8	21.0	20.8	11.8	18.4	55.7%	40.0
Agent for dry eye Mucosta ophthalmic suspension	Otsuka Pharmaceutical		0.1	1.0	2.9	2.8	1.6	2.1	28.8%	5.0
Parkinsons' disease, RLS* treatment Neupro Patch	Otsuka Pharmaceutical			0.2	2.6	4.7	2.2	3.6	64.3%	9.0
Anticancer SPRYCEL (collaboration with BMS)	Otsuka Pharmaceutical	8.0	7.6	12.0	26.1	22.9	12.6	15.5	22.8%	31.0
Antibiotic Zospin/Tazocin (bulk supply)	Taiho Pharmaceutical	11.2	10.7	12.4	14.5	11.8	8.0	6.1	-23.7%	13.0
Diagnostics -total	Otsuka Pharmaceutical	6.6	7.9	8.8	12.6	8.5	7.1	6.2	-12.7%	12.5
Parenteral nutrition (clinical nutrition) -total	Otsuka Pharmaceutical Factory	96.8	96.0	96.4	103.4	81.5	48.3	49.5	2.4%	106.5
Japan		87.6	88.6	88.8	91.6	68.2	40.4	41.2	2.0%	87.5
Others		9.2	7.4	7.6	11.8	13.3	7.9	8.2	4.2%	19.0
Pharmaceutical business -total (excluding exports)	Japan	319.9	326.5	351.8	372.9	273.7	171.0	181.1	6.0%	376.0
Pharmaceutical business -total	Total	751.1	782.2	850.9	1,035.1	883.5	533.7	520.9	-2.4%	903.0
Milestone and upfront revenue		7.3	14.9	41.5	22.0	20.4	12.0	32.2	167.7%	65.0

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate.
The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

*RLS: Restless legs syndrome

【Nutraceutical business】

(10 thousand cases)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year	2Q FY2015 (Jan-Jun)	Change
Pocari Sweat 1 case: 24 bottles, and other (10 thousand cases)	Otsuka Pharmaceutical								
Japan		3,234	2,912	2,709	2,860	2,006	1,136	1,202	5.8%
Overseas		1,597	1,963	2,151	2,684	2,256	1,338	1,326	-0.9%
SOYJOY 1 case: 48 bars (10 thousand cases)	Otsuka Pharmaceutical								
Japan		113	100	88	109	107	63	61	-3.5%
Overseas		28	20	12	16	12	9	10	8.6%
Oronamin C 1 case: 50 bottles (10 thousand cases)	Otsuka Pharmaceutical	1,051	1,081	1,067	1,105	830	495	488	-1.4%
Calorie Mate 1 case: 4 bars×30, and other (10 thousand cases)	Otsuka Pharmaceutical	392	351	335	340	280	165	182	9.9%
Tiovita Drink 1 case: 50 bottles (10 thousand cases)	Taiho Pharmaceutical	484	532	489	402	290	171	156	-9.0%
Solmack (10 thousand of bottles)	Taiho Pharmaceutical	1,571	1,579	1,588	1,479	1,174	603	588	-2.4%

* Overseas sales include sales of consolidated subsidiaries only.

【Consumer products business】

(10 thousand cases)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year	2Q FY2015 (Jan-Jun)	Change
Bottled Water 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	674	679	567	580	396	246	226	-8.2%
Match 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	371	451	521	514	447	271	249	-8.1%
Other (tea drinks and other) 1 case: 24 bottles (10 thousand cases)	Otsuka Foods	267	317	300	265	177	109	104	-5.0%

【Other business】

(Billions of yen)

Product name	Company	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year (consolidated)	2Q FY2015 (Jan-Jun)	Change
Functional chemicals	Otsuka Chemical	26.3	27.9	26.6	33.5	26.6	17.9	17.4	-3.1%
Fine chemicals	Otsuka Chemical	12.4	9.3	10.2	10.1	7.3	5.3	5.5	4.0%

II-2. Segment Information

Sales to Customers by Market

(Billions of yen)

Net sales by business segment	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year (unaudited)	2Q FY2015 (Jan-Jun)	Change
Consolidated sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	733.9	745.8	1.6%
Pharmaceutical business	751.1	782.2	850.9	1,035.1	883.5	533.7	520.9	-2.4%
Japan	319.9	326.5	351.8	372.9	273.7	171.0	181.1	6.0%
North America	349.0	361.1	389.0	530.5	481.6	286.3	229.9	-19.7%
Others	82.2	94.7	110.0	131.7	128.3	76.4	109.8	43.7%
Nutraceutical business	256.4	251.3	246.9	281.1	232.7	130.9	150.6	15.1%
Japan	154.1	147.4	142.3	147.5	109.8	64.0	65.7	2.5%
North America	46.8	45.8	49.8	59.8	55.8	25.0	36.4	45.8%
Others	55.6	58.1	54.8	73.9	67.1	41.8	48.5	16.0%
Consumer products business	47.1	48.0	45.2	43.8	34.4	21.4	20.7	-3.1%
Japan	40.9	42.0	39.2	36.6	27.9	17.2	15.6	-9.3%
North America	5.5	5.4	5.4	6.9	6.1	3.9	4.8	21.6%
Others	0.7	0.6	0.6	0.3	0.3	0.2	0.3	36.7%
Other business	72.9	73.1	75.0	92.8	73.7	47.9	53.5	11.7%
Japan	60.1	59.1	62.0	71.4	55.9	36.6	39.0	6.5%
North America	1.4	1.3	1.4	2.3	1.8	1.2	1.0	-19.1%
Others	11.4	12.7	11.6	19.0	16.0	10.2	13.6	34.0%
Japan -total	575.1	574.9	595.3	628.3	467.3	288.8	301.4	4.4%
North America - total	402.7	413.5	445.7	599.6	545.3	316.4	272.1	-14.0%
Others - total	149.8	166.2	177.1	224.9	211.7	128.7	172.3	33.9%
Overseas net sales	552.5	579.7	622.7	824.4	757.0	445.1	444.4	-0.1%
Overseas net sales ratio	49.0%	50.2%	51.1%	56.8%	61.8%	60.6%	59.6%	

Net Sales and Operating Income by Geographical Segment

(Billions of yen)

	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year (unaudited)	2Q FY2015 (Jan-Jun)	Change
Net sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	733.9	745.8	1.6%
Japan*	745.2	779.1	842.5	982.1	738.2	471.0	402.7	-14.5%
North America*	426.0	437.5	474.1	652.1	601.9	343.1	307.9	-10.2%
Others*	132.5	142.4	138.2	204.4	189.6	118.6	133.2	12.3%
Eliminations/corporate	-176.2	-204.4	-236.7	-385.9	-305.4	-198.8	-98.0	

*Intersegment sales are included.

(Billions of yen)

	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year (unaudited)	2Q FY2015 (Jan-Jun)	Change
Operating income	126.3	148.7	169.7	198.7	196.5	82.9	103.2	24.5%
Japan	106.3	142.5	160.8	217.5	156.2	87.1	47.7	-45.2%
North America	12.2	14.4	16.2	-5.0	12.8	5.4	6.6	21.2%
Others	6.8	3.7	6.4	1.9	16.8	-0.2	17.1	-
Eliminations/corporate	1.0	-12.0	-13.8	-15.7	10.7	-9.4	31.7	

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

II-3. Selling, General and Administrative Expenses

(Billions of yen)

Selling, general and administrative expenses	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year -unaudited-	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
Net sales	1,127.6	1,154.6	1,218.1	1,452.8	1,224.3	733.9	745.8	1.6%	1,380.0
Selling, general and administrative expenses	622.3	616.6	654.6	812.4	681.5	433.2	427.5	-1.3%	820.0
(% of net sales)	55.2%	53.4%	53.7%	55.9%	55.7%	59.0%	57.3%		59.4%
Promotion expenses	179.6	174.4	156.2	192.0	188.0	106.9	115.4	7.9%	
Personnel expenses	97.9	99.8	103.7	124.0	97.9	67.2	74.8	11.2%	
Advertising expenses	28.9	25.1	29.5	34.2	26.0	15.0	15.9	5.7%	
Research and development expenses	164.7	159.2	192.4	249.0	172.9	127.1	95.1	-25.2%	205.0
(% of net sales)	14.6%	13.8%	15.8%	17.1%	14.1%	17.3%	12.7%		14.9%
R&D expenses of pharmaceutical business	153.4	149.3	183.5	240.8	166.1	122.3	90.2	-26.3%	195.0

(Persons)

Number of employees (consolidated)	FY2010	FY2011	FY2012	FY2013	FY2014
Japan	14,030	13,808	13,732	14,116	14,285
Overseas	11,158	10,787	11,598	14,172	15,197
Pharmaceutical business	14,662	14,063	14,660	16,578	17,057
Number of sales representatives (Japan)	2,240	2,297	2,329	2,340	2,317
Nutraceutical business	5,740	5,422	5,729	6,405	7,022
Consumer products business	855	819	831	654	540
Other business	2,218	2,490	2,429	2,928	3,207
Corporate	1,713	1,801	1,681	1,723	1,656
Number of employees (consolidated)	25,188	24,595	25,330	28,288	29,482

(Billions of yen)

Capital expenditures	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year -unaudited-	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
Capital expenditures	44.8	43.3	63.3	179.0	88.2	39.6	414.0	374.4	450.0
Pharmaceutical business	24.5	20.8	38.0	154.5	31.7	24.9	400.0	375.1	
Nutraceutical business	11.9	11.5	14.9	10.1	31.9	6.7	5.7	-1.0	
Consumer products business	0.8	2.0	2.7	2.9	2.9	1.3	3.4	2.1	
Other business	2.9	4.6	4.0	4.4	18.6	2.9	4.0	1.1	
Corporate	4.7	4.5	3.7	7.1	3.2	3.8	0.9	-2.9	

(Billions of yen)

Depreciation	FY2010	FY2011	FY2012	FY2013	FY2014 (Apr-Dec) Standardizing the Company's business year	FY2014 (Jan-Jun) Standardizing the Company's business year -unaudited-	2Q FY2015 (Jan-Jun)	Change	Estimate FY2015 (Jan-Dec) (Forecast as of Aug 2015)
Depreciation	48.1	48.1	45.5	49.8	45.5	28.8	36.6	7.8	72.0
Pharmaceutical business	22.4	22.8	21.9	25.6	27.9	16.7	24.7	8.0	
Nutraceuticals business	14.8	13.1	12.1	13.3	9.6	6.6	6.7	0.1	
Consumer products business	0.9	2.1	2.0	1.7	1.2	0.8	0.7	-0.1	
Other business	5.2	5.1	4.6	4.5	3.7	2.4	2.5	0.1	
Eliminations/corporate	4.8	5.0	4.9	4.6	3.2	2.3	2.0	-0.3	

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate.
The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

III. Consolidated Balance Sheets

<Assets>						(Billions of yen)	
	As of March 31, 2011	As of March 31, 2012	As of March 31, 2013	As of March 31, 2014	As of December 31, 2014	As of June 30, 2015	Composition
Current assets	921.2	1,012.3	1,080.6	1,168.8	1,245.6	1,161.4	46.6%
Cash and deposits	387.5	411.6	414.4	455.3	523.1	474.3	
Notes and accounts receivable-trade	239.6	263.5	318.1	327.3	406.4	317.3	
Marketable securities	122.5	151.8	137.8	118.0	48.5	135.0	
Finished products and merchandise	62.3	60.8	71.2	83.8	80.0	81.7	
Work-in process	23.6	26.9	25.8	30.6	31.8	36.7	
Raw materials and supplies	28.9	31.7	35.3	37.4	41.9	42.5	
Deferred tax assets	24.6	34.3	40.8	54.5	37.8	-	
Other current assets	32.4	32.2	37.8	62.5	76.5	74.6	
Allowance for doubtful receivables	-0.4	-0.4	-0.5	-0.6	-0.5	-0.6	
Fixed assets	668.4	654.4	698.5	859.5	932.5	1,331.9	53.4%
Tangible fixed assets	256.8	255.5	276.0	315.2	344.8	352.1	
Intangible fixed assets	77.1	67.1	73.9	192.3	221.2	606.5	
Goodwill	41.4	36.8	37.8	70.6	93.2	476.5	
Other intangible fixed assets	35.6	30.3	36.1	121.7	128.0	130.0	
Investments and other assets	334.5	331.8	348.7	352.0	366.6	373.3	
Investment securities	261.2	267.0	276.3	268.5	270.8	275.0	
Investments in capital	22.0	23.3	31.6	36.0	42.5	44.7	
Long-term loans receivable	0.6	1.3	0.9	5.3	5.6	-	
Net defined benefit asset	-	-	-	11.1	17.5	23.0	
Deferred tax assets	32.2	25.3	26.5	16.9	15.5	-	
Other assets	21.3	16.3	15.8	15.0	15.5	31.3	
Allowance for investment loss	-2.8	-1.0	-1.6	-0.1	-0.1	-0.1	
Allowance for doubtful receivables	-0.1	-0.5	-0.8	-0.7	-0.8	-0.7	
Deferred assets	0.1	0.1	0.1	0.1	0.1	0.1	0.0%
Total assets	1,589.7	1,666.8	1,779.2	2,028.4	2,178.2	2,493.4	100.0%

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

<Liabilities>

(Billions of yen)

	As of March 31, 2011	As of March 31, 2012	As of March 31, 2013	As of March 31, 2014	As of December 31, 2014	As of June 30, 2015	Composition
Total liabilities	426.4	444.0	454.1	517.6	519.6	767.4	30.8%
Current liabilities	275.6	311.4	346.5	437.4	437.0	428.7	17.2%
Notes and accounts payable-trade	88.1	94.8	97.5	132.9	130.8	80.7	
Short-term borrowings	53.2	39.7	51.8	53.4	70.2	55.6	
Lease obligations	3.4	3.0	2.6	2.2	2.1	-	
Income taxes payable	13.3	33.8	33.5	51.1	14.5	10.8	
Reserve for bonuses	15.9	16.1	15.9	18.7	8.6	8.9	
Provision for directors' bonuses	0.3	0.4	0.3	0.6	0.6	0.1	
Provision for sales returns	0.1	0.1	0.2	0.1	0.0	-	
Other current liabilities	101.2	123.4	144.7	178.5	210.2	272.6	
Long-term liabilities	150.8	132.6	107.7	80.2	82.6	338.7	13.6%
Long-term debt	28.8	25.9	6.3	14.3	22.3	272.0	
Lease obligations	7.1	5.8	5.9	5.7	5.8	-	
Deferred tax liabilities	10.8	8.0	11.3	16.7	12.0	-	
Net defined benefit liability	-	-	-	8.1	10.9	11.1	
Liability for employees' retirement benefits	44.3	44.7	40.6	-	-	-	
Retirement benefits for directors' and audit & supervisory board members' retirement benefits	3.4	3.1	3.1	2.6	2.8	2.4	
Negative goodwill	28.9	26.5	24.0	21.5	19.7	18.5	
Other long-term liabilities	27.5	18.7	16.6	11.3	9.1	34.7	
<Net assets>							
Total net assets	1,163.3	1,222.8	1,325.1	1,510.8	1,658.6	1,726.0	69.2%
Shareholders' equity	1,202.3	1,267.7	1,342.0	1,438.3	1,537.9	1,585.3	63.6%
Common stock	81.7	81.7	81.7	81.7	81.7	81.7	
Capital surplus	510.6	510.6	510.4	512.9	512.7	512.7	
Retained earnings	610.0	675.4	768.3	891.6	990.9	1,038.2	
Treasury stock	-0.0	-0.0	-18.4	-47.9	-47.4	-47.3	
Accumulated other comprehensive income	-52.1	-59.1	-31.5	46.3	89.9	108.2	4.3%
Unrealized gain/loss on available-for-sale securities	0.4	0.8	8.3	13.8	13.2	25.9	
Deferred gain (loss) on derivatives under hedge accounting	-0.0	0.0	0.0	-0.0	0.4	-0.0	
Foreign currency translation adjustments	-52.4	-59.9	-39.8	12.2	57.2	64.7	
Remeasurements of defined benefit plans	-	-	-	20.3	19.2	17.7	
Stock acquisition rights	0.5	1.1	0.1	0.1	0.0	-	0.0%
Minority interests	12.7	13.0	14.5	26.1	30.8	32.5	1.3%
Total liabilities and net assets	1,589.7	1,666.8	1,779.2	2,028.4	2,178.2	2,493.4	100.0%

IV. Consolidated Statements of Cash Flows

	FY2010	FY2011	FY2012	FY2013	FY2014	2Q FY2015 (Jan-Jun)
(Billions of yen)						
Operating activities:						
Income before income taxes and minority interests	123.0	142.4	176.9	210.2	210.3	109.5
Depreciation and amortization	43.5	43.4	40.6	46.0	41.7	23.8
Impairment loss	2.8	2.7	2.6	3.4	5.4	0.1
Amortization of goodwill	2.1	2.2	2.4	1.1	2.0	11.4
Decrease (increase) in net defined benefit asset/ liability	-	-	-	-13.8	-9.6	-5.5
Increase in liability for employees' retirement benefits	0.3	0.5	-4.7	-	-	-
Increase (decrease) in allowance for doubtful receivables	-0.1	0.4	0.2	-0.2	-0.2	0.0
Increase in provision for loss on business liquidation	-	2.2	-0.3	-1.9	-	-
Interest and dividend income	-2.5	-2.8	-2.9	-2.5	-2.2	-1.8
Interest expense	1.5	1.7	1.2	1.2	1.7	2.0
Equity in earnings of unconsolidated subsidiaries and affiliated companies (gain)	-3.7	-1.2	-3.1	-3.2	-3.9	-5.1
Gain on sales of subsidiaries' stocks (gain)	-	-	-	-0.3	-	0.6
Gain on change in equity interest	-5.6	-0.3	-	-	-	-
Loss on transfer of business	1.9	0.7	-	-	-	-
(Increase) decrease in trade receivables	-17.0	-25.7	-47.2	12.4	-61.3	91.6
(Increase) decrease in inventories	-7.4	-7.4	-5.5	-1.8	17.7	-7.9
Increase (decrease) in trade payables	2.1	8.5	-3.9	19.6	-3.9	-49.5
Increase (decrease) in long-term unearned revenue	-7.3	-7.3	-1.9	-7.7	-5.6	-0.0
Other, net	8.1	17.3	25.7	23.3	-20.5	60.3
Subtotal	141.7	177.2	180.1	285.8	171.6	229.4
Interest and dividends received	7.9	6.9	7.2	8.0	7.1	3.6
Interest paid	-1.8	-2.0	-1.2	-1.2	-1.7	-1.8
Income taxes paid	-59.9	-34.4	-66.8	-66.1	-88.5	-3.7
Net cash provided by operating activities	87.7	147.6	119.3	226.5	88.5	227.5
Investing activities:						
(Increase) decrease in short-term investment securities	-	-7.0	-20.0	12.7	19.6	-41.3
Purchases of property, plant and equipment	-35.4	-36.0	-50.5	-48.9	-32.9	-31.7
Purchases of intangible assets	-	-	-	-21.2	-7.1	-12.8
Proceeds from sales of property, plant and equipment	0.5	0.7	0.3	1.2	0.5	0.1
Purchases of investment securities	-33.2	-31.4	-16.7	-5.3	-9.7	-4.1
Proceeds from sales and redemption of investment securities	27.7	17.4	16.2	12.4	1.3	6.5
Payments for investments in capital	-1.8	-0.3	-3.3	-1.1	-0.1	-
Proceeds from transfer of business	2.1	1.4	-	-	-	-
Payments for transfer of business	-	-1.3	-	-	-	-
Purchase of investments in subsidiaries resulting in change in scope of consolidation	-	-	-1.5	-95.4	-26.7	-383.9
Payments of loans receivables	-0.3	-2.3	-0.7	-22.3	-2.8	-0.6
Proceeds from collection of loans receivables	0.4	0.6	1.4	0.6	0.3	19.4
(Increase) decrease in time deposits-net	-85.8	-47.5	-9.1	59.1	28.5	15.1
Other, net	-5.8	-1.9	-7.3	-0.5	0.3	-0.7
Net cash used in investing activities	-131.5	-107.6	-91.2	-108.5	-28.7	-434.0
Financing activities:						
Increase (decrease) in short-term loans payable	-6.7	3.2	1.1	5.0	-4.2	-24.9
Proceeds from long-term loans payable	2.6	2.3	3.4	7.9	9.4	264.5
Repayments of long-term loans payable	-33.8	-23.8	-16.1	-13.0	-1.8	-2.9
Proceeds from issuance of common stock	77.5	-	-	-	-	-
Proceeds from disposal of treasury stock	85.2	-	0.2	0.4	0.4	0.1
Purchases of treasury stock	-	-	-20.0	-30.0	-0.0	-0.0
Dividends paid	-6.0	-26.8	-29.3	-32.8	-37.9	-21.7
Dividends paid to minority interest in consolidated subsidiaries	-0.4	-0.4	-0.5	-0.4	-0.4	-0.4
Proceeds from share issuance to minority shareholders	-	-	-	-	0.8	0.1
Other, net	-4.9	4.5	-10.7	-3.8	-2.2	-1.1
Net cash provided by (used in) financing activities	113.6	-41.1	-71.9	-66.7	-36.0	213.7
Foreign currency translation adjustment on cash and cash equivalents	-5.3	-1.4	6.2	9.5	14.3	-2.8
Net increase (decrease) in cash and cash equivalents	64.5	-2.4	-37.6	60.7	38.2	4.4
Cash and cash equivalents at beginning of period	321.3	387.3	384.2	347.6	417.5	456.5
Increase (decrease) in cash and cash equivalents due to change in scope of consolidation	1.5	-0.7	0.9	9.2	1.0	2.5
Decrease in cash and cash equivalents due to change of fiscal year end	-	-	-	-	-0.1	-
Cash and cash equivalents at end of period	387.3	384.2	347.6	417.5	456.5	463.5

* From 1Q FY2011, the method of translating revenue and expense accounts of foreign subsidiaries was changed from the spot rate as of the reporting date to the average exchange rate. The method of presentation for upfront licensing payments received was changed from non-operating income to net sales. Figures for FY2010 have been adjusted retrospectively to apply the changes above.

V. Shareholders

【Classification of shareholders】

(As of June 30, 2015)

Classification	Shareholder Information								Less than trading unit
	National and local government	Financial institutions	Financial instruments firms	Other institutions	Foreign investors		Private investors and others	Total	
					Other than individuals	Individuals			
Number of shareholders	-	128	32	414	644	24	49,234	50,476	-
Number of shares held (shares)	-	1,609,290	149,229	986,280	1,513,226	118	1,318,854	5,576,997	135,917
% of outstanding shares	-	28.86%	2.68%	17.68%	27.13%	0.00%	23.65%	100.00%	-

*Out of 15,987,751 shares of treasury stock, 159,877 share units are included in "Private investors and others", and 51 shares are included in "Less than trading unit"

**Shareholders who only own a number of shares that is less than a trading unit are included in "Number of shareholders".

【Principal shareholders】

(As of June 30, 2015)

Names	Address	Number of shares held	% of outstanding shares
		(thousand shares)	
The Nomura Trust & Banking Co. Otsuka Founders Shareholding Fund Trust Account	2-2-2 Otemachi, Chiyoda-ku, Tokyo	62,051	11.12
Japan Trustee Services Bank, Ltd. (Trust Account)	1-8-11 Harumi, Chuo-ku, Tokyo	47,085	8.44
Otsuka Estate Limited	3-3-3 Ote-Dori, Chuo-ku, Osaka	22,871	4.10
Otsuka Group Employee Shareholding Fund	2-16-4 Konan, Minato-ku, Tokyo	15,365	2.75
The Master Trust Bank of Japan, Co., Ltd. (Trust Account)	2-11-3 Hamamatsucho, Minato-ku, Tokyo	14,783	2.65
The Awa Bank, Limited	2-24-1 Nishisenba-cho, Tokushima	10,971	1.97
THR BANK OF NEWYORK MELLON SA/NV10 (standing proxy: The Bank of Tokyo-Mitsubishi UFJ, Ltd.)	RUE MONTOYERSTRAAT 46, 1000 BRUSSELES, BELGIUM (2-7-1 Marunouchi, Chiyoda-ku, Tokyo)	7,690	1.38
Otsuka Asset Co., Ltd.	17-4 Aza-Fukuike, Tosadomariura, Naruto-cho, Naruto City, Tokushima	7,380	1.32
STATE STREET BANK WEST CLIENT-TREATY 505234 (standing proxy: Mizuho Bank)	1776 HERITAGE DRIVE, NORTH QUINCY, MA 02171, USA (4-16-13 Tsukishima, Chuo-ku, Tokyo)	6,753	1.21
MEDIPAL HOLDINGS CORPORATION	2-7-15 Yaesu, Chuo-ku, Tokyo	6,148	1.10
ALL	-	201,097	36.04

*Shares of Japan Trustee Services Bank, Ltd. and The Master Trust Bank of Japan, Co., Ltd. are the sum of plural Trust Account.

**15,987,751 shares of treasury stock are excluded from principal shareholders, but included in calculating percentage of outstanding shares.

VI. Pipeline Information

Otsuka Group - Pipeline Information

(as of Jun 30, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Central nervous system, neurological disorders						
OPC-14597 <ABILIFY*>	aripiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Autism / Oral	JP	Phase III
<Abilify Maintena*>: Depot injection				Bipolar I / Depot injection	JP, US, EU	Phase III
				Agitation associated with dementia of the Alzheimer's type / Oral	JP	Phase III
L059 <E Keppra>	levetiracetam	UCB	Anti-epileptic drug	Epilepsy (generalized onset seizures) / Oral, Injection	JP	Filed
OPC-34712 <REXULTI*>	brexpiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US EU	Filed** Phase III
				Schizophrenia / Oral	US JP, EU	Filed** Phase III
				ADHD (Adults) / Oral	US	Phase II
				Agitation associated with dementia of the Alzheimer's type / Oral	US, EU	Phase III
				Posttraumatic stress disorder (PTSD) / Oral	US, EU	Phase III
Lu AE58054	idalopirdine	Lundbeck	selective 5-HT ₆ receptor antagonist	Alzheimer's disease / Oral	US, EU	Phase III
ASC-01	aripiprazole, sertraline	Otsuka Pharmaceutical	Dopamine partial agonist/ Selective serotonin reuptake inhibitor	Major depressive disorder / Oral	JP, Asia	Phase III
AVP-923	dextromethorphan, quinidine	Avanir	NMDA receptor inhibitor / Sigma 1 receptor agonist	Agitation associated with dementia of the Alzheimer's type / Oral	US	Phase II
				Dyskinesia associated with Parkinson's disease / Oral	US	Phase II
AVP-786	deuterium-modified dextromethorphan, quinidine	Avanir	NMDA receptor inhibitor / Sigma 1 receptor agonist	Adjunctive therapy for major depressive disorder / Oral	US	Phase II
AVP-825	sumatriptan	Avanir	5-HT _{1B/1D} receptor agonist	Acute migraine / Nasal powder	US	Filed
TAS-205		Taiho Pharmaceutical	PGD synthase-inhibitor	Duchenne Muscular Dystrophy (DMD) / Oral	JP	Phase I
Lu AA36143	nalmefene	Lundbeck	Opioid receptor antagonist	Lowering alcohol consumption of alcohol dependence / Oral	JP	Phase III
Lu AF20513		Lundbeck	β -amyloid vaccine	preventing progression of Alzheimer's demetia/injection	EU	Phase I

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

** : Events after June 30, 2015 brexpiprazole/ Schizophrenia, Adjunctive therapy for major depressive disorder: approved on July in US

Otsuka Group - Pipeline Information

(as of Jun 30, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Oncology						
S-1 <TS-1> Japan, Korea <Teyuno*> EU	tegafur, gimeracil, oteracil	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Uterocervical cancer / Oral	JP, Asia	Phase III
TAS-102 <Lonsurf>	trifluridine, tipiracil	Taiho Pharmaceutical	Anti-cancer	Colorectal cancer / Oral	US, EU Asia	Filed Phase III
TAS-118	tegafur, gimeracil, oteracil, folinate	Taiho Pharmaceutical	Anti-cancer (Anti-metabolite)	Pancreatic cancer / Oral	JP, Asia	Phase III
				Gastric cancer / Oral	JP, Asia	Phase III
<SATIVEX*>	nabiximols	GW Pharmaceuticals	Cannabinoid (THC, CBD)	Cancer pain / Oral spray	US	Phase III
OCV-101		OncoTherapy Science	Therapeutic cancer vaccine	Pancreatic cancer / Injection	JP	Phase II
<SPRYCEL>	dasatinib	BMS	Anti-cancer (Molecular-targeted drug)	Pancreatic cancer / Oral	US, EU	Phase II
SGI-110	guadecitabine	Astex	Anti-cancer	Ovarian cancer / Injection	US, EU	Phase II
				Hepatocellular carcinoma / Injection	US, EU	Phase II
				Acute Myeloid Leukemia, Myelodysplastic syndrome / Injection	US	Phase II
				Acute Myeloid Leukemia / Injection	US, EU	Phase III
				Acute Myeloid Leukemia / Injection	JP	Phase I
AT13387		Astex	Anti-cancer (Molecular-targeted drug)	Prostate cancer / Injection	US, EU	Phase II
				NSCLC / Injection	US, EU	Phase II
AT7519		Astex	Anti-cancer (Molecular-targeted drug)	Multiple myeloma / Injection	US	Phase II
ASTX727		Astex	Anti-cancer	Myelodysplastic syndrome / Oral	US	Phase I
ET-743	trabectedin	PharmaMar	Anti-cancer	Malignant soft tissue sarcoma / Injection	JP	Filed
OPB-31121		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, Asia	Phase I
OPB-51602		Otsuka Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Anti-cancer / Oral	JP, US, Asia	Phase I
OPB-111077		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	US, Asia	Phase I
OPB-111001		Otsuka Pharmaceutical	Anti-cancer	Solid tumors / Oral	EU	Phase I
TAS-114		Taiho Pharmaceutical	Anti-cancer (Antitumor enhancer)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-115		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-116		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-117		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
TAS-119		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	US, EU	Phase I
TAS-120		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP, US, EU	Phase I
TAS-121		Taiho Pharmaceutical	Anti-cancer (Molecular-targeted drug)	Solid tumors / Oral	JP	Phase I
OCV-501		Otsuka Pharmaceutical	WT1 targeted cancer vaccine	Secondary Prevention of elderly acute myeloid leukemia / Injection	JP, Asia	Phase II
OCV-C02		OncoTherapy Science	Therapeutic cancer vaccine	Colorectal Cancer / Injection	JP	Phase I
OPC-12759	rebamipide	Otsuka Pharmaceutical	Oral mucosal protectant / mucosal healing agent	Stomatitis associated with cancer chemoradiotherapy / Solution	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
*: Product names used outside Japan.

Otsuka Group - Pipeline Information

(as of Jun 30, 2015)

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status
Cardiovascular						
OPC-41061 <SAMSCA*/JINARC*>	tolvaptan	Otsuka Pharmaceutical	V ₂ receptor antagonist	Hepatic edema / Oral	Asia	Filed
				Autosomal dominant polycystic kidney disease / Oral	EU US Asia	Approved Phase III Filed
				Cardiac edema / Oral	Asia	Filed
				Carcinomatous edema / Oral	JP	Phase II
				Volume overload in hemodialysis / Oral	JP	Phase II
				Volume overload in peritoneal dialysis/ Oral	JP	Phase II
OPC-108459		Otsuka Pharmaceutical		Paroxysmal and persistent atrial fibrillation / Injection	JP, US	Phase I
Other areas						
YP-18 <ZOSYN*>	tazobactam, piperacillin	Taiho Pharmaceutical	Antibiotic agent	Febrile neutropenia / Injection	JP	Approved
TAC-202	bilastine	Faes Farma	H ₁ receptor antagonist	Allergic rhinitis / Oral	JP	Phase III
				Chronic urticaria, Pruritus associated with skin disease/ Oral	JP	Phase II / III
OPC-67683 <Delyba*>	delamanid	Otsuka Pharmaceutical	Anti-tuberculosis agent	Multidrug-resistant tuberculosis / Oral	US	Phase III
				Multidrug-resistant tuberculosis for pediatrics / Oral	EU	Phase II
OPC-12759E <Mucosta Ophthalmic Suspension>	rebamipide	Otsuka Pharmaceutical	Mucin-production enhancing agent	Dry eyes / Eye drops MD (Multi Dose)	JP	Phase III
OPB-2045G	olanexidin	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Filed**
OPF-105	Amino Acid, Carbohydrate, and Fat Emulsion Injection with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Peripheral parenteral nutrition solution / Injection	JP	Phase III
OPF-108	Amino Acid and Carbohydrate, and with Electrolytes and Vitamins	Otsuka Pharmaceutical Factory	Protein and amino acid preparation	Total parenteral nutrition / Injection	JP	Phase III
OPC-6535	tetomilast	Otsuka Pharmaceutical	Anti-inflammatory agent	COPD / Oral	JP, US, Asia	Phase II
ACU-4429	emixustat	Acucela	Visual cycle modulator	Dry AMD / Oral	US	Phase II b / III
OPA-6566		Otsuka Pharmaceutical	A _{2a} receptor agonist	Glaucoma / Eye Drops	US	Phase I / II
OPC-1085EL	carteolol, latanoprost	Otsuka Pharmaceutical	β receptor antagonist / PGF _{2α} analogue	Glaucoma / Eye Drops	JP	Phase III
OPA-15406		Otsuka Pharmaceutical	PDE4 inhibitor	Atopic Dermatitis / Ointment	US	Phase II
Diagnostics						
C13-URA	Uracil (2-13C)	Otsuka Pharmaceutical	13C-uracil breath test	For the diagnosis of gastric emptying disorders / In-vivo diagnostic drug	US	Phase II
C13-CAC	Calcium (13C)	Otsuka Pharmaceutical	13C-Calcium Carbonate breath test	For measurement of gastric acidity / In-vivo diagnostic agent	JP	Phase II

Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.

*: Product names used outside Japan.

** : Events after June 30, 2015 olanexidin/ Patient preoperative preparation: approved on July in JP

Changes in Pipeline information Since March 2015

Code / <Brand name>	Generic name	Origin	Category	Indication / Dosage form	Country / Region	Development status	Change from 2015 1Q
Central nervous system, neurological disorders							
Lu AF20513		Lundbeck	β -amyloid vaccine	preventing progression of Alzheimer's dementia/injection	EU	Phase I	Newly Added
Cardiovascular							
OPC-41061 <SAMSCA*/JINARC*>	tolvaptan	Otsuka Pharmaceutical	V ₂ receptor antagonist	Autosomal dominant polycystic kidney disease / Oral	EU	Approved	Filed→Approved
				Autosomal dominant polycystic kidney disease / Oral	Asia	Filed	Newly Added
Other areas							
YP-18 <ZOSYN*>	tazobactam, piperacillin	Taiho Pharmaceutical	Antibiotic agent	Febrile neutropenia / Injection	JP	Approved	Filed→Approved
<Events after June 30, 2015>							
OPC-34712 <REXULTI*>	brexiprazole	Otsuka Pharmaceutical	Dopamine partial agonist	Adjunctive therapy for major depressive disorder / Oral	US	Approved (July 2015)	
				Schizophrenia / Oral	US	Approved (July 2015)	
OPB-2045G	olanexidin	Otsuka Pharmaceutical Factory	Anti-septics	Patient preoperative preparation / Topical	JP	Approved (July 2015)	

*: Product names used outside Japan.



Otsuka-people creating new products
for better health worldwide